C difficile risk
Oral Bioavailability


20-30mg/kg/DAY divided q8-12h. Max: 400mg/DOSE

20mg/kg/DAY divided q12h. Max: 500mg/DOSE

30-40mg/kg/DAY divided q12h. Max: 750mg/DOSE

Cystic fibrosis Max: 1000mg/DOSE

Severe infection (limited data): IV 20mg/kg/DAY divided q12h

Use with caution in severe hepatic dysfunction

Renally cleared, requires dosage adjustment with changes in renal function. Consult a pharmacist for renal dosing.

General Information

Pseudomonal and other gram negative infections of urinary tract, bone/joint, abdomen, and other sites

Renal and liver function, CBC. QTc in patients with increased risk.

Tendinopathy and rupture, retinal detachment, peripheral neuropathy have been reported.

Dizziness, insomnia, rash, n/v, abdominal pain.

Tendinopathy and rupture, retinal detachment, peripheral neuropathy & QTc prolongation have been reported.

Strong CYP1A2 inhibitor and weak CYP3A4 inhibitor - Multiple interactions possible
QTc prolongation - Increased risk with other agents that prolong QTc

AVOID concomitant administration with antacids, multivitamin & mineral supplements. Space doses by 2 hours.

Increased risk of tendon rupture with concomitant use of corticosteroids.

Monitor INR with warfarin.

Not routinely first-line therapy in children.

Antimicrobial class: Fluoroquinolone

Average serum half life: Pediatrics: 4-5 hours

Route of Elimination: 30% to 50% excreted as unchanged drug in urine via glomerular filtration and active tubular secretion; 20% to 40% excreted in feces primarily from biliary excretion; <1% excreted in bile as unchanged drug